Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison

OBJECTIVE: PATENT-1 and CHEST-1 were pivotal, international phase III trials assessing riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Here we compare Chinese patients from these studies with the overall populations, and report the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chen, Jing, Zhi-Cheng, Huang, Yi-Gao, Zhou, Da-Xin, Liu, Zhi-Hong, Meier, Christian, Nikkho, Sylvia, Curram, John, Zhang, Peng, He, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898635/
https://www.ncbi.nlm.nih.gov/pubmed/27326239
http://dx.doi.org/10.1136/heartasia-2015-010712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898635/
https://www.ncbi.nlm.nih.gov/pubmed/27326239
http://dx.doi.org/10.1136/heartasia-2015-010712

Ejemplares similares